Taysha Gene Therapies Cash on Hand 2020-2024 | TSHA

Taysha Gene Therapies cash on hand from 2020 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Taysha Gene Therapies Annual Cash on Hand
(Millions of US $)
2023 $144
2022 $88
2021 $149
2020 $251
2019 $
Taysha Gene Therapies Quarterly Cash on Hand
(Millions of US $)
2024-09-30 $158
2024-06-30 $173
2024-03-31 $124
2023-12-31 $144
2023-09-30 $164
2023-06-30 $45
2023-03-31 $63
2022-12-31 $88
2022-09-30 $34
2022-06-30 $66
2022-03-31 $97
2021-12-31 $149
2021-09-30 $189
2021-06-30 $197
2021-03-31 $229
2020-12-31 $251
2020-09-30 $279
2020-06-30
2020-03-31
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.379B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $24.142B 7.92
Dr Reddy's Laboratories (RDY) India $12.621B 24.15
BridgeBio Pharma (BBIO) United States $4.953B 0.00
Bausch Health Cos (BHC) Canada $2.672B 1.97
Supernus Pharmaceuticals (SUPN) United States $1.975B 26.90
Amphastar Pharmaceuticals (AMPH) United States $1.894B 11.38
Personalis (PSNL) United States $0.372B 0.00
Assembly Biosciences (ASMB) United States $0.100B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.008B 0.00
Teligent (TLGT) United States $0.000B 0.00